Abstract
The p38 MAP kinases are a family of serine/threonine protein kinases that play a key role in cellular pathways leading to pro-inflammatory responses. We have developed and implemented a method for rapidly identifying and optimizing potent and selective p38α inhibitors, which is amenable to other targets and target classes. A diverse library of druggable, purified and quantitated molecules was assembled and standardized enzymatic assays were performed in a microfluidic format that provided very accurate and precise inhibition data allowing for development of SAR directly from the primary HTS. All compounds were screened against a collection of more than 60 enzymes (kinases, proteases and phosphatases), allowing for removal of promiscuous and non-selective inhibitors very early in the discovery process. Follow-up enzymological studies included measurement of concentration of compound in buffer, yielding accurate determination of Ki and IC50 values, as well as mechanism of action. In addition, active compounds were screened against less desirable properties such as inhibition of the enzyme activity by aggregation, irreversible binding, and timedependence. Screening of an 88,634-compound library through the above-described process led to the rapid identification of multiple scaffolds ( > 5 active compounds per scaffold) of potential drug leads for p38α that are highly selective against all other enzymes tested, including the three other p38 isoforms. Potency and selectivity data allowed prioritization of the identified scaffolds for optimization. Herein we present results around our 3-thio-1,2,4-triazole lead series of p38α selective inhibitors, including identification, SAR, synthesis, selectivity profile, enzymatic and cellular data in their progression towards drug candidates.
Keywords: serine/threonine protein kinases, drug discovery, anti-cytokine biotherapeutics, sar, high throughput screening, library design, thio- triazole
Current Topics in Medicinal Chemistry
Title: Discovery of Highly Selective Inhibitors of p38α
Volume: 5 Issue: 10
Author(s): Ioana Popa-Burke, Steve Birkos, Leonard Blackwell, Lynn Cheatham, Jennifer Clark, John K. Dickson, Jr., Scott Galasinski, William P. Janzen, Jose Mendoza, Jennifer L. Miller, Robert P. Mohney, Paul M. Steed and C. N. Hodge
Affiliation:
Keywords: serine/threonine protein kinases, drug discovery, anti-cytokine biotherapeutics, sar, high throughput screening, library design, thio- triazole
Abstract: The p38 MAP kinases are a family of serine/threonine protein kinases that play a key role in cellular pathways leading to pro-inflammatory responses. We have developed and implemented a method for rapidly identifying and optimizing potent and selective p38α inhibitors, which is amenable to other targets and target classes. A diverse library of druggable, purified and quantitated molecules was assembled and standardized enzymatic assays were performed in a microfluidic format that provided very accurate and precise inhibition data allowing for development of SAR directly from the primary HTS. All compounds were screened against a collection of more than 60 enzymes (kinases, proteases and phosphatases), allowing for removal of promiscuous and non-selective inhibitors very early in the discovery process. Follow-up enzymological studies included measurement of concentration of compound in buffer, yielding accurate determination of Ki and IC50 values, as well as mechanism of action. In addition, active compounds were screened against less desirable properties such as inhibition of the enzyme activity by aggregation, irreversible binding, and timedependence. Screening of an 88,634-compound library through the above-described process led to the rapid identification of multiple scaffolds ( > 5 active compounds per scaffold) of potential drug leads for p38α that are highly selective against all other enzymes tested, including the three other p38 isoforms. Potency and selectivity data allowed prioritization of the identified scaffolds for optimization. Herein we present results around our 3-thio-1,2,4-triazole lead series of p38α selective inhibitors, including identification, SAR, synthesis, selectivity profile, enzymatic and cellular data in their progression towards drug candidates.
Export Options
About this article
Cite this article as:
Popa-Burke Ioana, Birkos Steve, Blackwell Leonard, Cheatham Lynn, Clark Jennifer, Dickson, Jr. K. John, Galasinski Scott, Janzen P. William, Mendoza Jose, Miller L. Jennifer, Mohney P. Robert, Steed M. Paul and Hodge N. C., Discovery of Highly Selective Inhibitors of p38α, Current Topics in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/1568026054985867
DOI https://dx.doi.org/10.2174/1568026054985867 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Scaffolds for Blocking Protein-Protein Interactions
Current Topics in Medicinal Chemistry Adenovirus Vectors Composed of Subgroup B Adenoviruses
Current Gene Therapy Potential Use of Food Protein-Derived Peptides in the Treatment of Inflammatory Diseases
Protein & Peptide Letters Pancreatic Islets Under Attack: Cellular and Molecular Effectors
Current Pharmaceutical Design Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Biomarkers for Predicting the Immunomodulatory Properties of Probiotics
Recent Patents on Biomarkers Beyond Promoter: The Role of Macrophage in Invasion and Progression of Renal Cell Carcinoma
Current Stem Cell Research & Therapy “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Small Non-Coding RNAs as Novel Therapeutics
Current Molecular Medicine Strategic Combination Therapies for Ovarian Cancer
Current Cancer Drug Targets Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Acute <i>Versus</i> Chronic Administration of Calcineurin-Inhibitors Differentially Affect T-Cell Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms of Polyphenols in Management of Skin Aging
Current Aging Science Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy